Title of article :
Perioperative chemotherapy and hepatic resection for resectable colorectal liver metastases
Author/Authors :
beppu, toru kumamoto university hospital - department of multidisciplinary treatment for gastroenterological cancer, Kumamoto, Japan , sakamoto, yasuo kumamoto university hospital - department of multidisciplinary treatment for gastroenterological cancer, Kumamoto, Japan , hayashi, hiromitsu kumamoto university - graduate school of life sciences - department of gastroenterological surgery, Kumamoto, japan , baba, hideo kumamoto university - graduate school of life sciences - department of gastroenterological surgery, Kumamoto, Japan
Abstract :
The role of perioperative chemotherapy in the management of initially resectable colorectalliver metastases (CRLM) is still unclear. The EPOC trial [the European Organization for Research andTreatment of Cancer (EORTC) 40983] is an important study that declares perioperative chemotherapyas the standard of care for patients with resectable CRLM, and the strategy is widely accepted in westerncountries. Compared with surgery alone, perioperative FOLFOX therapy significantly increasedprogression-free survival (PFS) in eligible patients or those with resected CRLM. Overall survival (OS) datafrom the EPOC trial were recently published in The Lancet Oncology, 2013. Here, we discussed the findingsand recommendations from the EORTC 40983 trial.
Keywords :
Colorectal liver metastases (CRLM) , perioperative chemotherapy , the European Organization forResearch and Treatment of Cancer (EORTC) trial (40983)Submitted Jul 25, 2014. Accepted for publication Jul 29,
Journal title :
Hepatobiliary Surgery and Nutrition
Journal title :
Hepatobiliary Surgery and Nutrition
